Immunity-Boosting Natural Herbs to Combat COVID-19 Pandemic:  A Narrative Review by Nimesh, Saurabh et al.
Borneo Journal of Pharmacy http://journal.umpalangkaraya.ac.id/index.php/bjop/article/view/2534  
Vol 4 Issue 4 November 2021 DOI: https://doi.org/10.33084/bjop.v4i4.2534 




Recently, pandemic diseases have become of great 
importance in terms of enormous morbidity even with 
the extensive facilities available in medical sciences1. 
More importantly, the antiviral drugs have failed to give 
the requisite results due to the more resistant mutant 
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Coronaviruses cause some severe forms of respiratory infections such 
as Severe acute respiratory syndrome (SARS), Middle East respiratory 
syndrome (MERS), and Coronavirus disease 2019 (Covid-19). These 
viruses cause diarrhea in pigs and cows and upper respiratory disease 
in chickens, while other symptoms may differ. In humans, a total of 
six coronaviruses have been identified HCoVs-NL63, HCoVs-OC43, 
HCoVs-229E, HCoVs-HKU1, MERS-CoV, and SARS-CoV. The world 
health organization (WHO) has done a great deal of hard work 
regarding combating the monstrous effects of this virus. So far, no 
specific antiviral drugs have been developed for the treatment of 
Covid-19. Therefore, the medicinal plants used for the previous 
epidemic outbreaks are getting attention for their potential treatment 
against the virus. It has been reported that 70 to 80% of people in 
developing countries depend on medicinal plants or phytomedicine 
compared to allopathic drugs for their primary healthcare. The south 
Asian subcontinents have used almost up to 25,000 formulations and 
extracts obtained from medicinal plants for treatment in folk medicine. 
The present review discusses an overview of the coronavirus, its 
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forms of viruses that have emerged over time2. Due to the 
fast urbanization and improved availability of travel 
facilities, contagious diseases have been spread more 
easily, posing a danger to communal safety and health 
integrity3. In the twenty-first century, two fatally 
devastating viral outbreaks have been observed by 
humans: The Middle East respiratory syndrome 
coronavirus (MERS-CoV) and severe acute respiratory 
syndrome coronavirus (SARS-CoV) population of our 
planet4. Recently, coronavirus disease 2019 (Covid-19) 
caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is the third most important 
disease that originated from an animal source and spread 
worldwide after starting in Wuhan, China5. 
Experts have studied the clinical presentation of this 
virus, and it has been confirmed that it resembles much 
pneumonia and therefore has been named the novel 
coronavirus (2019-nCoV). Investigations have acquired 
that in sequence homology SARS-CoV resembles bat 
coronavirus. The spike glycoproteins of the virus are seen 
to have a massive affinity for Angiotensin-converting 
enzyme 2 (ACE2) receptors in humans. This property 
enables the virus to undergo human-to-human 
transmission6. The virus diagnosis and transmission 
ability vary in comparison with SARS-CoV despite the 
huge resemblance they share. The distinction lies mainly 
in the nucleotide pattern of spike proteins as well as its 
receptor-binding domains7.  
World Health Organization (WHO) has done a great 
deal of hard work regarding combating the monstrous 
effects of this virus. For example, they have made the 
populations aware of how to halt the spread of the 
disease by minimization of physical contact, isolating and 
screening the infected people in the early stages, as well 
as recognizing and reducing the transmission from the 
animals8. The virus is known to spread through aerosol 
pathways as well as through saliva and the nose. As long 
as no vaccine is available, scientists worldwide have been 
putting a significant number of efforts into finding out the 
best way to prevent the spread of this fatal disease9. On 
the other hand, manufacturers have been working on 
manufacturing sanitizers and masks, which have been 
profitable to ordinary people and health care 
professionals. With the diseases still spreading at an 
incredible speed, it is imperative to unveil the 
pathogenesis of the virus so that suitable drugs and 
vaccines can be designed10.  
Many treatment options are being discovered, but there 
is a severe lack of valid evidence to support their use. 
Multiple drugs are in the waiting of clinical trials. While 
that is to be done, the already available antiviral drugs 
such as lopinavir, nitazoxanide, chloroquine, ritonavir, 
tocilizumab, hydroxychloroquine, and azithromycin 
have been used for management and are seen to dwindle 
the replication and reduce the load of the virus11,12. 
Scientists are working fast to achieve their target of 
protecting the public. Monoclonal antibodies, steroids, 
peptides, oligonucleotides, interferons, enzyme 
inhibitors have been suggested to restrain the spread of 
disease13,14. To manage the clinical presentation of SARS-
CoV-2 unproven vaccines, antiviral drugs, and other 
alternatives have been tried imposing stress on 
symptoms management and precautions15. The 
discovery of a new drug requires months to years as the 
drug is tested through clinical trials and improved based 
on the results16. However, there is a great demand to 
combat the Covid-19 outbreak, bring relief to those 
suffering, and save lives for which natural medicines, 
medicinal plants, and herbal formulations should now be 
sent for warfare. They are feasible and cost-effective, eco-
friendly, efficacious, with almost no side effects when 
used accordingly17. 
One herb contains plenty of phytochemicals that are very 
effective pharmacologically, either collectively or single-
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handedly18. These naturally occurring constituents are 
isolated and modulated into new drugs used to treat 
different ailments. In recent years, medicinal plants are 
the way to go for managing the symptoms and treating 
their cause, and research is being done to encourage their 
usage for treating patients with Covid-19 as these herbs 
possess antioxidant, anti-inflammatory, and antiviral 
characteristics19. Through this review, we suggest using 
phytomedicine as an alternative approach to treat and 
manage the diseases caused by these fatal viruses as 
described in Figure 1. 
 




Coronavirus is derived from the Latin word 
Orthocoronavirinae is one subfamily from the two of 
Coronaviridae family and is known to cause ailments in 
mammals and birds. Because of its specific crown-like 
shape, the virus is called a corona. Serologically and 
genotypically, the subfamily of coronavirus constitutes 
four specific types: alpha, beta, gamma, and delta 
coronavirus20. There are also four different subgroups of 
coronavirus, including A, B, C, and D. As of today, the 
total of identified coronaviruses infecting mammals, 
poultry, humans, and other animals has reached up to 
thirty and cause various ailments of hepatic, 
gastrointestinal, neurological, and particularly the 
respiratory types21. In humans, a total of six 
coronaviruses have been identified HCoVs-NL63, 
HCoVs-OC43, HCoVs-229E, HCoVs-HKU1, MERS-
CoV, and SARS-CoV22. It is already reasonably known 
that the diameter of the virus is 120 nanometers. A pair of 
electron-dense cells make up the envelope of the virus, as 
seen through electron microscopy23.  
Coronavirus is a ribonucleic acid (RNA) virus of a single 
strand. Only the alpha and beta coronaviruses cause 
infectious diseases in humans5. The survival of the virus 
depends upon its medium and can survive at room 
temperature on dry surfaces and in feces for two to three 
days and two to four days, respectively24. The genomic 
RNA of the virion is seen to be embedded in double 
layers of a phospholipid, and two different kinds of 
nucleocapsid protein coat the virion. The membrane 
protein (M protein) is a transmembrane glycoprotein of 
type-3. Both the M protein and the envelope protein are 
included in the surface proteins (S proteins) of the virus's 
envelope25. In the early steps of viral infection, the 
multifunctional S protein plays a vital role by interacting 
with the proteases and receptors of the host cell. As a 
result of these interactions, human cells containing 
contain hACE2 transmembrane proteins are infected26. 
 
IMMUNOPATHOLOGY 
The infection caused by coronavirus is classified into 
three stages. The first is the asymptomatic stage, while the 
second and third are the symptomatic stages of the viral 
disease, with the second being non-severe and the third 
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being the severe stage27. Most patients recover before 
progressing to the third severe stage of the disease, while 
the few develop multiorgan failure or acute respiratory 
distress syndrome (ARDS). When SARS-CoV-2 attaches 
with ACE2 receptors and lets out the viral RNA for the 
process of replication, the host’s immunity begins to 
respond to the invader28.  
In response to the viral invasion, both the adaptive and 
innate immune responses can be produced29. However, 
the immune responses depend on the severity of the 
infection. It has been shown that in the blood samples of 
hospitalized patients with mild to moderate symptoms 
of SARS-CoV-2 infection before the symptoms resolved, 
several immunological changes were observed, such as 
an increase in the number of active CD8+ killer T cells and 
CD4+ helper T cells, antibody-secreting cells, follicular 
helper T cells, and immunoglobulin (Ig) G and IgM 
antibodies were detected30. In contrast to this, in severely 
ill patients, there is a decrease in the numbers of B cells, 
natural killer cells, CD3+ T cells, CD8+ killer T cells, CD4+ 
helper T cells, as well as a rise in the neutrophil-to-
lymphocyte ratio (NLR) and levels of C-reactive protein. 
Moreover, in serum samples of critically ill patient’s 
tumor necrosis factor (TNF)-α, granulocyte-colony 
stimulating factor, interleukin (IL)-2, IL-6, IL-7, IL-8, IL-10, 
macrophage inflammatory protein-1α, and monocyte 
chemoattractant protein-1 are reported to be elevated in 
contrast with non-severe patients31,32. 
The NLR is a biomarker for the systemic inflammatory 
response and indicates the devastating inflammatory 
stage of critically ill patients33. An overactive 
inflammatory response is produced in response to the 
uncontrolled levels of chemokines and cytokines and is 
also called a cytokine storm. The impairment of the 
adaptive immune response along with these hyperactive 
responses of immune systems leads to pulmonary injury, 
viral sepsis, ARDS, and complications of organ failure, 
and in some cases, death34. 
 
SIGNS AND SYMPTOMS 
According to the Centers for Disease Control and 
Prevention (CDC), the median incubation period for 
Covid-19 is four to five days. It varies from person to 
person. However, it can range anywhere from two to 14 
days. It affects a different person in different ways1. The 
most infected person will develop mild to moderate 
illness and recover without hospitalization; not every 
person with a Covid-19 infection will feel unwell. It is 
possible to have the virus and not develop any 
symptoms. When symptoms are present, they are 
typically mild and develop slowly35.  
According to researchers in China, these were the most 
common symptoms like fever, fatigue, nausea and 
vomiting, cough, runny or stuffy nose, mucus/phlegm, 
sore throat, lack of appetite (anorexia), muscle aches and 
pains (myalgia), shortness of breath (dyspnea), headache, 
diarrhea, chills, loss of taste or smell, and conjunctivitis36. 
The severity of Covid-19 symptoms can range from very 
mild to severe. Some people may experience severe or 
worsened symptoms, such as difficulty breathing or 
shortness of breath, pneumonia, chest pain, loss of speech 
or movement, about a week after symptoms start. Older 
people with pre-existing chronic medical conditions have 
a higher risk of serious illness from Covid-19, and the risk 
increases with age37. 
 
DIAGNOSIS 
Upon diagnosis with the suspected infection, a patient 
gets to confirm whether a suffering from Covid-19 or not. 
The CDC recommends two testing strategies for SARS-
CoV-2. In the first strategy, a patient's blood sample is 
screened for the possible presence of antibodies against 
the virus, and in the second strategy, viral 
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deoxyribonucleic acid (DNA) is screened for a sputum 
sample. The virus can be detected in case of infection, but 
to make sure polymerase chain reaction (PCR) is 
performed, PCR takes a more extended hour than the 
screen of patient blood method38.  
The collection of an appropriate specimen is the crucial 
step in the laboratory diagnosis of Covid-19. The 
specimens are accepted from the upper respiratory tract, 
lower respiratory tract, stool, whole blood, and serum, 
and the respiratory secretions are the most frequent 
sample for diagnosis. Nowadays, SARS-CoV-2 has been 
detected in the swabs of nasopharyngeal, oropharyngeal, 
throat, sputum, bronchoalveolar lavage fluid (BALF), 
whole blood, serum, stool, urine, saliva, rectal and 
conjunctival39. A comparison of different nucleic acid 
amplification of SARS-CoV-2, including laboratory-
based tests and point-of-care tests, is shown in Table I. 
Table I. Characteristics and the merits-demerits of different laboratory diagnostic methods for SARS-CoV-240-42 
SARS-CoV-2 
tests 








Bio-safety level-2 (BSL-2) 
or BSL-3 laboratory, 
pathogen laboratory 
Authoritative, simple, low 
cost, reliable, highly sensitive 
Time-consuming, long 
period, laborious, perform 









BSL-2 laboratory, public 
health institutes, 
quarantine depots 











Automatic, portable, rapid, 
not require trained staff 
Inconsistent performance 
may lack sensitivity in 






community nursing sites 
Time-saving, thermostatic, 
sensitive, user-friendly, 
sophisticated equipment free 
Easy to be contaminated 
and cause false positive, 
non-specific amplification 







High sensitivity, adopted in 
fully automated RNA 
extraction systems, excellent 
RNA binding performances 
Complex pre-treatment 
steps require skillful, 
expensive than qRT-PCR, 
with the risk of 
photobleaching  
Nested RT-PCR BSL-2 laboratory, 
prefectural and 
municipal public health 
institutes, quarantine 
depots 
High sensitivity, specificity 
was higher than that of RT-
PCR, suitable for detecting 
low copy number viruses, 
time-saving 
Complex pre-treatment 
steps require skillful, 
manpower, the second 
PCR amplification may 
cause cross-contamination 




suitable for detecting 
samples with low viral load, 
independent of a traditional 
standard curve 
Susceptible to exogenous 
contamination, expensive 
than qRT-PCR, calibrant 








public health institutes 
Quantitative detection, 
simple, a low risk of 















Rapid, convenient, onsite 




performance, not suitable 








Small size, high sensitivity, 
automatic, high throughput, 
portable 
Core technologies lack 
norms and standards, high 






public health institutes 
Avoid the interference of 
endogenous biotin and 











public health institutes 
Automatic, rapid, 
quantitative, high sensitivity, 
broad linear range, stable 
results 
Sophisticated instruments, 
high requirements for 
equipment and 
environment, not suitable 






BSL-2 laboratory, genetic 
testing centers, research 
laboratory 
Simple, reduce the cost, does 
not claim a reference 
sequence 
Increase cost, sophisticated 
instruments, insufficient 
coverage, and depth 
Hybrid capture-
based sequencing 
BSL-2 laboratory, genetic 
testing centers, research 
laboratory 




not to be used to sequence 




BSL-2 laboratory, genetic 
testing centers, research 
laboratory 
Broad detection range, rapid 
turnaround time, long read, 
high accuracy, monitor the 
variation 





BSL-2 laboratory, genetic 
testing centers, research 
laboratory 
Convenient, high sensitivity, 
suitable for detecting 
samples with low viral load, 
economical 
Sophisticated instruments, 




MEDICINAL PLANTS FOR COVID-19 
So far, no specific drugs (antiviral) therapy or vaccines 
have been developed to treat Covid-19; the medicinal 
plants used for the previous epidemic and pandemic 
outbreaks are getting attention for their potential 
treatment against the virus43. Chinese herbal medicine is 
an essential part of Chinese traditional medicine and has 
been one of the most robust models of herbal medicine 
for about 2000 years by using about 10,000 medicinal 
plants as extracts of warm water to control contagious 
diseases44. It has been reported that 70 to 80%of people in 
developing countries depend on medicinal plants or 
phytomedicine compared to allopathic drugs for their 
primary healthcare45. The benefits obtained from the 
medicinal herbs are contributed by the presence of the 
plant’s secondary metabolites such as steroids, 
diterpenes, alkaloids, glycosides, and aliphatics, and 
others46. 
The investigations for discovering a plant metabolite 
with antiviral activity have been ongoing but not very 
successful due to the ability of viruses to mutate and 
adapt resistance and undergo latency and the persistence 
of infections in patients with a weak immune system47. 
Moreover, the antiviral therapy modules are mostly not 
specific for viruses while exerting their antiviral activity48. 
Medical research has been working hard to develop 
novel antiviral mediators at present. The antiviral 
constituents of the various medicinal plants play an 
essential role in combating viral diseases by exerting 
effects at the various stages of viral replication and 
growth49. 
Traditional medicine has been used for a long time in the 
Indian subcontinent and has played important roles in 
fighting off the various ailments and providing primary 
healthcare to communities at a much efficient and 
affordable cost50. The traditional subcontinental 
medicines include Ayurveda, Unani, Homeopathy, 
Siddha, Naturopathy, and Yoga and are being used to 
treat various infectious ailments50. Animals, plants, and 
minerals have been used for treatment by these medical 
models51. The south Asian subcontinents have used 
almost up to 25,000 formulations and extracts obtained 
from medicinal plants for treatment in folk medicine52. 
Following are some of the antiviral, immunostimulant, 
and immunomodulating agents, which belong to 
medicinal plants. Various studies have recommended 
their isolated compounds to potentially use in the battle 
against the Covid-19, as shown in Tables II and III. 
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Cannabis sativa 
A study carried out by Wang et al.53 on cannabinoid and 
cannabidiol reported that an active constituent of C. sativa 
showed that the constituent has anti-inflammatory 
properties as it modulates the gene expression of ACE2, 
the protein required for the coronavirus entry into the 
host cell and transmembrane protease, serine 2. It can be 
used as an adjunctive therapy and as a mouthwash as 
well as throat gargle because it reduces the entry of the 
virus through the oral mucosa. 
Glycyrrhiza glabra 
A study carried out by Bailly and Vergoten54 on 
glycyrrhizin, liquiritin, glycyrrhizic acid, and isoliquiritin; 
active constituents of G. glabra, showed that the plant has 
antiviral properties and can be used as a potential 
antiviral herbal drug against Covid-19.  
Citrus species 
A study was carried out by Meneguzzo et al.55 on 
essential oils, naringin, pectins, and hesperidin 
(flavonoids) belonging to citrus species showed that they 
have a high affinity of binding with the SARS-CoV-2 
cellular receptors, which puts a halt to the overreaction of 
the immune system before the inflammatory process 
begins. This particular action enables it to be used as 
prophylaxis as well as a potential treatment for Covid-19. 
Another study on citrus species showed that naringin, 
hesperetin, naringenin, and hesperidin have an 
inhibitory effect on the pro-inflammatory cytokines 
(inducible nitric oxide synthase, cyclooxygenase-2, IL-1β, 
IL-6) expression belonging to the cell line of macrophage, 
and also halted the effect of cytokines by inhibition of 
expression of high mobility group box protein 1 in a 
model of mouse and hindered the ACE2 receptor 
binding affinity of coronavirus56. The anti-inflammatory 
activity of the citrus species owing to the phytochemicals 
derived from flavonoids ensures the usage of the species 
as a potential treatment module of Covid-1957. 
Nigella sativa 
Banerjee et al.58 reported that N. sativa could be used as a 
potential treatment against the infection of SARS-CoV-2 
as two of its active constituents; α-hederin and 
nigelledine, act as the CoVs proteases inhibitors by 
docking into their active sites. 
Camellia sinensis 
Polyphenols of C. sinensis or black tea act as protease 
inhibitors by targeting the main protease of Covid-19, 
which is involved in the replication and transcription of 
the virus. This way, the plant can hinder the growth of 
the virus inside the host cell. Black tea can be used in the 
diet to help the body fight against Covid-19 when the 
disease is still in the early stages59. 
Zingiber officinale 
Zingiber officinale can be used as a potential treatment 
drug against Covid-19 as it inhibits the Covid-19 main 
protease R7Y by binding with its active sites. The active 
ingredient attributing to this particle property is 6-
gingerol57,60. 
Cnidoscolus aconitifolius 
The plant is reported to have the most potent inhibitory 
effect on the ACE2 enzyme, modulated expression of α-
gene for the production of TNF in macrophages, and 
anti-inflammatory properties. These plant characteristics 
are attributed to the presence of phenols, flavanones, 
flavonoids, and dihydroflavonols61. 
Scutellaria baicalensis 
The plant is reported to inhibit replication and SARS-
CoV-2 3-chymotrypsin-like cysteine protease and can be 
effective for inhibiting the virus62. 
Ginkgo biloba 
Ginkgo biloba is reported to dwindle protein and 
Deoxyribonucleic acid synthesis by binding with the cell 
receptors of the host and is due to the presence of 
ginkgolic acids and can be used for the treatment of 
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coronavirus infections63. Moreover, another study shows 
that terpenoids and ginkgolide have a strong binding 
affinity with the coronavirus proteases and therefore can 
be used as potential antiproteases for Covid-1964. 
Allium sativum 
The plant’s essential oils and active constituents, such as 
allyl disulfide and allyl trisulfide, are reported to be 
involved in ACE2 receptor inhibition as well as inhibition 
of SARS-CoV-2 main proteins. Essential oils help restrain 
the entry of viruses into the body by acting as antiviral 
compounds and can be used for the fight against Covid-
1965. 
Table II. List of the 46 isolated phytochemical compounds 

















Saikosaponin B2 Bupleuri 
radix 
Saponin EC50: 1.7±0.1 
mmol/L 
Saikosaponin A Bupleuri 
radix 






Polyphenol EC50: 4.5 μM 
Luteolin Reseda 
luteola 
Flavonoid EC50: 10.6 μM 
Sinigrin Brussels Polyphenol IC50: 217 μM 
β-sitosterol Leucaena 
leucochepala 
Phytosterol IC50: 1210 μM 
Hesperetin Citrus Flavonoid IC50: 8.3 μM 
Amentoflavone Gingko 
biloba 
Flavonoid IC50: 8.3 μM 
Luteolin Reseda 
luteola  
Flavonoid IC50: 20.2 μM 
Quercetin Allium cepa Flavonoid IC50: 23.8 μM 
Apigenin Citrus Flavonoid IC50: 280.8 μM 
Isobavachalcoone Psoralea 
corylifolia 
Flavonoid IC50: 7.3±0.8 μM 
Psoralidin Psoralea 
corylifolia 
Flavonoid IC50: 4.2±1.0 μM 
Tomentin A Jatropha 
curcas 
Flavonoid IC50: 6.2±0.04 
μM 
Tomentin B Jatropha 
curcas 
Flavonoid IC50: 6.1±0.02 
μM 
Tomentin E Jatropha 
curcas 








Flavonoid IC50: 61.9±11.0 
μM 




Flavonoid IC50: 116.3±7.1 
μM 
Kazinol F Broussonetia 
kazinoki 
Flavonoid IC50: 43.3±10.4 
μM 
Broussochalcone B Broussonetia 
papyrifera 
Flavonoid IC50: 57.8±0.5 
μM 
Papyriflavonol A Broussonetia 
papyrifera 








Triterpene IC50: 9.9±0.1 μM 
Iguesterin Catha 
cassinoides  
Triterpene IC50: 2.6±0.3 μM 
Pristimererin Celastrus Triterpene IC50: 5.5±0.7 μM 
Dihydrotanshinone I Salvia 
miltiorrhiza 
Diterpene IC50: 4.9±1.2 μM 
Cryptotanshinone Salvia 
miltiorrhiza 
Diterpene IC50: 0.8±0.2 μM 
Tanshinone IIA Salvia 
miltiorrhiza 








Diarylheptanoid IC50: 3.0±1.1 μM 
Rubranoside Alnus 
glutinosa 
Diarylheptanoid IC50: 7.2±2.2 μM 
Curcumin Curcuma Diarylheptanoid IC50: 5.7 μM 
Allium porrum 
agglutinin 












Xanthone EC50: 3 μg/mL Human 
coronavirus 
229E Pyranojacareubin Calophyllum 
inophyllum 
Xanthone EC50: 15 μg/mL 
Tylophorine Incertae 
sedis  




Boehmeria Alkaloid EC50: 20±1 nM 
Jubanine G Zizyphus 
jujuba 




diarrhea virus Jubanine H Zizyphus 
jujuba 
Alkaloid EC50: 4.49±0.67 
μM 
Nummularine B Berberis 
nummularia 




Triterpene EC50: 0.28±0.09 
μM 
 
Table III. Summary of the 15 promising medicinal plants and 












Stronger bond and 
high affinity with 
proteases 
Compounds may 



















with active residues 
of ACE2 that 






efficacy before the 
recommendation 
Allium sativum (allyl 
disulfide, allyl 
trisulfide) 
Acted as ACE2 
receptor inhibitor for 
resistance against 
SARS-CoV-2 along 
with activity against 
main proteases of 
SARS-CoV-2 





































































action by via 
modulation of gene 
expression of anion 
exchange protein 2 
enzymes, 
transmembrane 
protease, serine 2, 
protein pre-requisite 
for SARS-CoV-2 
invasion into host 
cells 
Adjunct therapy 




and home use 
owing to their 
potential to 
decrease viral 
entry via the oral 
mucosa 





Binds with high 
affinity to cellular 
receptors of SARS-
CoV-2 that restrain 
the pro-
inflammatory 












infractions of extract 


































that routes virus 










Potent inhibitors of 
coronaviruses that 
inhibit the binding 
or internalization of 
the virus into the 
host cells 
Biocompatible 
compounds can be 
used as a coating 
material on 







affinity with viral 
and host 
macromolecular 






human ACE2, and 
furin proteins 
Regularly 
consumed in the 
form of Ayurvedic 
Kadha to boost 
immunity and 





Scientists are burning night oils in finding out the ways to 
treat Covid-19. However, due to higher ability of the 
virus to mutate and adaptation to resistance has imposed 
several limitations. Plant extracted formulations are cost-
effective, eco-friendly, and have nil to rare side effects. 
Several plant extracts are used in the treatment of several 
diseases. Scientists can work on finding out the efficacy of 
the mentioned drug on the SARS-CoV-2. Some of these 
formulations might be proved a treatment measure. 
They may also reduce the lethality of the disease, along 
with helping in alleviating the symptoms. These extracts 
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